Skip to content

Drug interactions

Caplacizumab + Dabigatran etexilate

Severity: Major

Caplacizumab and Dabigatran etexilate: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Caplacizumab blocks von Willebrand factor-platelet binding and impairs primary hemostasis, and dabigatran adds anticoagulant effect. Together they increase the risk of serious bleeding.

What this interaction means in plain words

Caplacizumab and Dabigatran etexilate can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Caplacizumab belongs to Cardiovascular; Dabigatran etexilate belongs to Cardiovascular.

Evidence level: Moderate

Why it happens

Additive hemostatic impairment: antiplatelet-like vWF inhibition plus direct thrombin inhibition.

What to do

Avoid concurrent use where possible; if anticoagulation is essential, monitor closely for bleeding and consider holding dabigatran during caplacizumab treatment. Withhold both before invasive procedures per labeling.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Caplacizumab and Dabigatran etexilate, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Caplacizumab with Dabigatran etexilate?

MediHelp rates the interaction as major. Caplacizumab and Dabigatran etexilate can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Caplacizumab blocks von Willebrand factor-platelet binding and impairs primary hemostasis, and dabigatran adds anticoagulant effect. Together they increase the risk of serious bleeding.

How serious is the interaction between Caplacizumab and Dabigatran etexilate?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use where possible; if anticoagulation is essential, monitor closely for bleeding and consider holding dabigatran during caplacizumab treatment. Withhold both before invasive procedures per labeling.

What other medicines interact with Dabigatran etexilate?

MediHelp also lists interactions of Dabigatran etexilate with, for example, Defibrotide, Ketorolac, Mifepristone. The full list is on the Dabigatran etexilate page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in